Table 2. Antimicrobial susceptibility of 135 Chryseobacterium indologenes isolates (µg/mL).
| Antimicrobial agent | S (%) | I (%) | R (%) | MIC50 | MIC90 | Susceptibility breakpoint | MIC range |
|---|---|---|---|---|---|---|---|
| Cefotaxime | 0.0 | 5.9 | 94.1 | >128 | >128 | ≤8 | 1–128 |
| Ceftazidime | 6.7 | 5.9 | 87.4 | >128 | >128 | ≤8 | 1–128 |
| Piperacillin-tazobactam | 37.0 | 9.6 | 53.3 | >128/4 | >128/4 | ≤16/4 | 1/4–128/4 |
| Cefoperazone-sulbactam | 10.4 | 3.0 | 86.7 | >128/64 | >128/64 | ≤8/4 | 1/0.5–128/64 |
| Imipenem | 0.7 | 1.5 | 97.8 | >64 | >64 | ≤4 | 0.5–64 |
| Meropenem | 0.0 | 2.2 | 97.8 | >64 | >64 | ≤4 | 0.5–64 |
| Norfloxacin | 13.3 | 3.0 | 83.7 | >32 | >32 | ≤2 | 0.25–32 |
| Levofloxacin | 14.8 | 0.7 | 84.4 | 32 | >32 | ≤2 | 0.25–32 |
| Gatifloxacin | 14.1 | 1.5 | 84.4 | >32 | >32 | ≤2 | 0.25–32 |
| Ciprofloxacin | 12.6 | 0.7 | 86.7 | >32 | >32 | ≤1 | 0.25–32 |
| Moxifloxacin | 23.7 | 20.0 | 56.3 | 8 | >32 | ≤2 | 0.25–32 |
| Nemonoxacin | 5.2 | 0.0 | 94.8 | >32 | >32 | ≤2 | 0.25–32 |
| Amikacin | 0.7 | 1.5 | 97.8 | >128 | >128 | ≤16 | 1–128 |
| Minocycline | 98.5 | 0.7 | 0.7 | 2 | 4 | ≤4 | 0.5–64 |
| TMP-SMZ | 97.8 | 0.0 | 2.2 | 0.5/9.5 | 1/19 | ≤2/38 | 0.125/2.375–16/304 |
| Rifampicin | 72.6 | 3.7 | 23.7 | 0.5 | 16 | ≤1 | 0.25–32 |
S, susceptible; I, intermediate; R, resistant; MIC, minimal inhibitory concentration; MIC50, minimal inhibitory concentration for 50% isolates; MIC90, minimal inhibitory concentration for 50% isolates; TMP-SMZ, trimethoprim-sulfamethoxazole.